Candida sp. rRNA Results: What Molecular Testing Detects

By Your Health Magazine Health Information Team

A “Candida sp. rRNA detected” result means a molecular test found genetic material associated with one or more Candida yeast species in the tested sample, usually a vaginal swab. It supports the presence of Candida but does not, by itself, prove that the yeast is causing an active infection. Healthcare professionals interpret the result together with symptoms, examination findings, the specimen type, and other test results.

What Does “Candida sp. rRNA” Mean?

Candida is a group of yeasts that can normally live on the skin and in areas such as the mouth, intestines, and vagina. Under certain conditions, the yeast may overgrow and cause candidiasis. In the vagina, this is commonly called a vaginal yeast infection or vulvovaginal candidiasis.

On a laboratory report:

Candida identifies the genus, or group, of yeast being tested.
“sp.” means the result may represent a species within that group rather than one specifically identified species.
RNA or rRNA refers to genetic material used as the test’s molecular target. The precise RNA target depends on the assay.
Detected means the target was found above the test’s reporting threshold.
Not detected means the target was not found at a reportable level in that sample.

These tests are generally nucleic acid amplification tests, or NAATs. Instead of waiting for yeast to grow in a laboratory dish, they amplify a selected genetic target so it can be detected. The FDA maintains information about nucleic acid-based diagnostic tests, including vaginal assays that detect Candida-related targets.

Which Candida Species Does the Result Include?

The answer depends on the laboratory and test platform. A result labeled simply “Candida species” may combine several species into one group rather than naming the individual organism.

For example, one commonly used FDA-cleared vaginal molecular assay groups Candida albicans, Candida tropicalis, Candida parapsilosis, and Candida dubliniensis together. It reports Candida glabrata separately. Other tests may target a different collection of species or use different wording.

Example result	General interpretation
Candida species detected	At least one species covered by the assay’s Candida group was found.
Candida species detected; C. glabrata not detected	A grouped Candida target was found, but the separate C. glabrata target was not.
Candida species not detected; C. glabrata detected	The separate C. glabrata target was found even though the grouped target was negative.
Both detected	Targets from both reporting categories were found.
Not detected	No covered Candida target was found at a reportable level; this does not rule out every possible yeast species or every infection.
Invalid	The laboratory could not produce a valid result, and another test or specimen may be needed.

The report’s test name, methodology, and explanatory notes are therefore important. “Candida sp. rRNA detected” does not automatically mean Candida albicans unless the assay specifically identifies it.

Does a Detected Result Confirm a Yeast Infection?

Not always. Candida may be present in the vagina without causing itching, inflammation, discharge, or other symptoms. The CDC’s guidance on vulvovaginal candidiasis notes that finding Candida without related signs or symptoms is generally not, by itself, an indication for treatment.

A detected result is more consistent with symptomatic vulvovaginal candidiasis when it accompanies findings such as:

Vulvar or vaginal itching and burning
Redness, swelling, soreness, or small skin cracks
Thick vaginal discharge
Pain during sexual activity
Burning or discomfort with urination, especially when urine contacts irritated external tissue

These symptoms are not unique to Candida. Bacterial vaginosis, trichomoniasis, sexually transmitted infections, skin conditions, allergic reactions, and hormonal changes can cause overlapping symptoms. A vaginal panel may therefore test for several possible causes at the same time.

A Candida vaginal result also should not be interpreted as evidence of Candida in the bloodstream or internal organs. Invasive candidiasis occurs mainly in people with significant medical risk factors and requires different specimens and testing methods.

What the Test Cannot Tell You

A qualitative Candida molecular result usually does not show:

How much yeast is present: “Detected” is not a count and does not grade infection severity.
Whether Candida is causing the symptoms: Clinical context remains essential.
The exact species: Grouped assays may include several possible species.
Which antifungal medicine will work: Molecular detection generally does not provide antifungal susceptibility results.
Whether all Candida species have been excluded: A negative test applies only to the organisms and targets covered by that assay.
Whether another condition is also present: More than one cause of vaginal symptoms can occur at the same time.

This is one reason laboratory findings should not be used to select treatment without appropriate clinical evaluation. The general concept—testing biological material for specific molecular targets—is also used in many other areas of medicine, including molecular testing in lung cancer, although the specimens, targets, and clinical decisions are very different.

Molecular Testing Compared With Microscopy and Culture

Method	What it looks for	Important limitation
Molecular test	Selected Candida nucleic acid targets	May group species and usually does not test antifungal susceptibility
Microscopy or wet preparation	Yeast cells, budding forms, hyphae, or pseudohyphae	Yeast may be missed when only a small amount is present
Fungal culture	Yeast that grows from the specimen	Results take longer, and growth does not automatically prove that Candida caused the symptoms

Culture can be especially useful when symptoms are recurrent, severe, unusual, or unresponsive to initial care. It may provide more specific organism identification and can sometimes support susceptibility testing. The MedlinePlus overview of yeast infection tests explains how specimen collection and fungal cultures may be used for infections in different parts of the body.

Factors That Affect Interpretation

The significance of a Candida sp. rRNA result can vary based on:

Whether symptoms and visible inflammation are present
The body site and type of specimen tested
Which species the specific assay covers
Recent antifungal or antibiotic use
Pregnancy
Diabetes or problems with blood sugar control
A weakened immune system or immunosuppressive treatment
A history of recurrent vaginal yeast infections
Results for bacterial vaginosis, trichomoniasis, or other infections

People who continue to have symptoms despite a negative Candida result may need evaluation for another cause or a species that the test does not cover. Likewise, persistent symptoms with a detected result may require confirmation, species identification, or assessment for another condition rather than repeated self-treatment.

When to Seek Care

Contact a primary care professional, gynecologist, or other qualified clinician if this is your first suspected yeast infection, the laboratory result is unclear, symptoms keep returning, or symptoms do not improve after appropriate care. Medical guidance is particularly important during pregnancy or for people with diabetes, weakened immunity, severe symptoms, or a history of difficult-to-treat infections.

Seek prompt evaluation for fever, chills, significant pelvic or abdominal pain, vomiting, sores, bleeding unrelated to menstruation, or foul-smelling discharge. These are not typical features of a straightforward vaginal yeast infection and may indicate another condition.

A clinician can match the Candida sp. rRNA result to your symptoms and determine whether additional examination, culture, species identification, or other testing is appropriate. For broader consumer health information, visit the MedlinePlus health topics library.